Flemming Steen JA, rgensen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1456501/publications.pdf

Version: 2024-02-01

185998 2,569 82 28 citations h-index papers

47 g-index 83 83 83 3170 docs citations times ranked citing authors all docs

214527

#	Article	IF	CITATIONS
1	Synthesis and Structure–Activity Relationships of Novel Non-Steroidal CYP17A1 Inhibitors as Potential Prostate Cancer Agents. Biomolecules, 2022, 12, 165.	1.8	8
2	Is the unique benzodiazepine structure interacting with CYP enzymes to affect steroid synthesis in vitro?. Journal of Steroid Biochemistry and Molecular Biology, 2021, 205, 105765.	1.2	0
3	PTR2/POT/NPF transporters: what makes them tick?. Advances in Protein Chemistry and Structural Biology, 2021, 123, 219-240.	1.0	9
4	Biased cytochrome P450-mediated metabolism via small-molecule ligands binding P450 oxidoreductase. Nature Communications, 2021, 12, 2260.	5.8	34
5	Discovery of Novel Non-Steroidal Cytochrome P450 17A1 Inhibitors as Potential Prostate Cancer Agents. International Journal of Molecular Sciences, 2020, 21, 4868.	1.8	6
6	Molecular Dynamics Simulations Reveal the Proton:Peptide Coupling Mechanism in the Bacterial Proton-Coupled Oligopeptide Transporter YbgH. ACS Omega, 2019, 4, 2040-2046.	1.6	3
7	SMARTCyp 3.0: enhanced cytochrome P450 site-of-metabolism prediction server. Bioinformatics, 2019, 35, 3174-3175.	1.8	53
8	Structural analysis of Cytochrome P450 BM3 mutant M11 in complex with dithiothreitol. PLoS ONE, 2019, 14, e0217292.	1.1	5
9	Fast Methods for Prediction of Aldehyde Oxidase-Mediated Site-of-Metabolism. Computational and Structural Biotechnology Journal, 2019, 17, 345-351.	1.9	16
10	Both Reactivity and Accessibility Are Important in Cytochrome P450 Metabolism: A Combined DFT and MD Study of Fenamic Acids in BM3 Mutants. Journal of Chemical Information and Modeling, 2019, 59, 743-753.	2.5	13
11	An Optimized Screen Reduces the Number of GA Transporters and Provides Insights Into Nitrate Transporter 1/Peptide Transporter Family Substrate Determinants. Frontiers in Plant Science, 2019, 10, 1106.	1.7	17
12	The anti-epileptic drug lamotrigine inhibits the CYP17A1 lyase reaction in vitroâ€. Biology of Reproduction, 2018, 99, 888-897.	1.2	3
13	Dissecting the Cytochrome P450 1A2―and 3A4â€Mediated Metabolism of Aflatoxin B1 in Ligand and Protein Contributions. Chemistry - A European Journal, 2017, 23, 2884-2893.	1.7	31
14	Structure-based optimisation of non-steroidal cytochrome P450 17A1 inhibitors. Chemical Communications, 2017, 53, 3118-3121.	2.2	9
15	The low binding affinity of D-serine at the ionotropic glutamate receptor GluD2 can be attributed to the hinge region. Scientific Reports, 2017, 7, 46145.	1.6	15
16	Mechanism of Cytochrome P450 17A1-Catalyzed Hydroxylase and Lyase Reactions. Journal of Chemical Information and Modeling, 2017, 57, 1123-1133.	2.5	24
17	Aldehyde Oxidase: Reaction Mechanism and Prediction of Site of Metabolism. ACS Omega, 2017, 2, 4237-4244.	1.6	33
18	Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors. Scientific Reports, 2016, 6, 29468.	1.6	43

#	Article	IF	Citations
19	Insights into regioselective metabolism of mefenamic acid by cytochrome <scp>P</scp> 450 <scp>BM</scp> 3 mutants through crystallography, docking, molecular dynamics, and free energy calculations. Proteins: Structure, Function and Bioinformatics, 2016, 84, 383-396.	1.5	29
20	Enantioselective endocrine disrupting effects of omeprazole studied in the H295R cell assay and by molecular modeling. Toxicology in Vitro, 2016, 34, 71-80.	1.1	13
21	Salt Bridge Swapping in the EXXERFXYY Motif of Proton-coupled Oligopeptide Transporters. Journal of Biological Chemistry, 2015, 290, 29931-29940.	1.6	40
22	Density Functional Theory Study on the Formation of Reactive Benzoquinone Imines by Hydrogen Abstraction. Journal of Chemical Information and Modeling, 2015, 55, 660-666.	2.5	8
23	Prediction of cytochrome P450 mediated metabolism. Advanced Drug Delivery Reviews, 2015, 86, 61-71.	6.6	78
24	Use of density functional theory in drug metabolism studies. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 215-227.	1.5	25
25	A Robust Force Field Based Method for Calculating Conformational Energies of Charged Drug-Like Molecules. Journal of Chemical Information and Modeling, 2012, 52, 409-419.	2.5	5
26	Synthesis and Antiangiogenic Activity of N-Alkylated Levamisole Derivatives. PLoS ONE, 2012, 7, e45405.	1.1	8
27	A Steered Molecular Dynamics Study of Binding and Translocation Processes in the GABA Transporter. PLoS ONE, 2012, 7, e39360.	1.1	26
28	In Silico Predictions of hERG Channel Blockers in Drug Discovery: From Ligand-Based and Target-Based Approaches to Systems Chemical Biology. Combinatorial Chemistry and High Throughput Screening, 2011, 14, 375-387.	0.6	44
29	G Protein- and Agonist-Bound Serotonin 5-HT2A Receptor Model Activated by Steered Molecular Dynamics Simulations. Journal of Chemical Information and Modeling, 2011, 51, 315-325.	2.5	47
30	Identification of CYP1A2 ligands by structure-based and ligand-based virtual screening. MedChemComm, 2011, 2, 853.	3.5	8
31	A Quantitative Structure–Activity Relationship for Translocation of Tripeptides via the Human Proton-Coupled Peptide Transporter, hPEPT1 (SLC15A1). AAPS Journal, 2010, 12, 385-396.	2.2	24
32	Homology Modelling of the GABA Transporter and Analysis of Tiagabine Binding. ChemMedChem, 2010, 5, 986-1000.	1.6	50
33	Computational Prediction of Binding Affinity for CYP1A2-Ligand Complexes Using Empirical Free Energy Calculations. Drug Metabolism and Disposition, 2010, 38, 1347-1354.	1.7	33
34	Mutational Mapping and Modeling of the Binding Site for (S)-Citalopram in the Human Serotonin Transporter. Journal of Biological Chemistry, 2010, 285, 2051-2063.	1.6	91
35	Classification of Cytochrome P450 1A2 Inhibitors and Noninhibitors by Machine Learning Techniques. Drug Metabolism and Disposition, 2009, 37, 658-664.	1.7	91
36	Discovery of Ligands for the Human Intestinal Diâ€∤Tripeptide Transporter (hPEPT1) Using a QSARâ€Assisted Virtual Screening Strategy. ChemMedChem, 2009, 4, 1439-1445.	1.6	8

#	Article	IF	Citations
37	Virtual Screening and Prediction of Site of Metabolism for Cytochrome P450 1A2 Ligands. Journal of Chemical Information and Modeling, 2009, 49, 43-52.	2.5	78
38	Solvent Diversity in Polymorph Screening. Journal of Pharmaceutical Sciences, 2008, 97, 2145-2159.	1.6	51
39	hERG Classification Model Based on a Combination of Support Vector Machine Method and GRIND Descriptors. Molecular Pharmaceutics, 2008, 5, 117-127.	2.3	91
40	QSAR Models for the Human H+/Peptide Symporter, hPEPT1:  Affinity Prediction Using Alignment-Independent Descriptors. Journal of Chemical Information and Modeling, 2008, 48, 233-241.	2.5	25
41	Computational prediction of solubilizers' effect on partitioning. International Journal of Pharmaceutics, 2007, 329, 46-52.	2.6	4
42	Determination of protein conformation by isotopically labelled cross-linking and dedicated software: Application to the chaperone, calreticulin. International Journal of Mass Spectrometry, 2007, 268, 217-226.	0.7	16
43	Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia. Blood, 2006, 107, 2904-2911.	0.6	55
44	New leads of metallo- \hat{l}^2 -lactamase inhibitors from structure-based pharmacophore design. Bioorganic and Medicinal Chemistry, 2006, 14, 2627-2635.	1.4	50
45	Prediction of pH-Dependent Aqueous Solubility of Druglike Molecules. Journal of Chemical Information and Modeling, 2006, 46, 2601-2609.	2.5	84
46	Development of a QSAR Model for Binding of Tripeptides and Tripeptidomimetics to the Human Intestinal Di-/Tripeptide Transporter hPEPT1. Pharmaceutical Research, 2006, 23, 483-492.	1.7	18
47	In vitro evaluation of N-methyl amide tripeptidomimetics as substrates for the human intestinal di-/tri-peptide transporter hPEPT1. European Journal of Pharmaceutical Sciences, 2006, 28, 325-335.	1.9	7
48	Conformational restrictions in ligand binding to the human intestinal di-/tripeptide transporter: implications for design of hPEPT1 targeted prodrugs. Bioorganic and Medicinal Chemistry, 2005, 13, 1977-1988.	1.4	10
49	Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates. Bioinformatics, 2005, 21, 2145-2160.	1.8	98
50	Docking and scoring of metallo- \hat{l}^2 -lactamases inhibitors. Journal of Computer-Aided Molecular Design, 2004, 18, 287-302.	1.3	29
51	Isolation of a Library of Aromadendranes fromLandolphiadulcisand Its Characterization Using the VolSurf Approach. Journal of Natural Products, 2004, 67, 799-805.	1.5	18
52	Evaluation and Comparison of 3D-QSAR CoMSIA Models for CDK1, CDK5, and GSK-3 Inhibition by Paullones. Journal of Medicinal Chemistry, 2004, 47, 22-36.	2.9	98
53	HETEROTROPIC MODULATION OF SULFOTRANSFERASE 2A1 ACTIVITY BY CELECOXIB: PRODUCT RATIO SWITCHING OF ETHYNYLESTRADIOL SULFATION. Drug Metabolism and Disposition, 2004, 32, 1260-1264.	1.7	12
54	Human peptide transporters: therapeutic applications. Expert Opinion on Therapeutic Patents, 2002, 12, 1329-1350.	2.4	48

#	Article	IF	Citations
55	Structural Differences of Matrix Metalloproteinases with Potential Implications for Inhibitor Selectivity Examined by the GRID/CPCA Approach. Journal of Medicinal Chemistry, 2002, 45, 2675-2684.	2.9	90
56	Assessing the relative importance of the biophysical properties of amino acid substitutions associated with human genetic disease. Human Mutation, 2002, 20, 98-109.	1.1	39
57	A New Concept for Multidimensional Selection of Ligand Conformations (MultiSelect) and Multidimensional Scoring (MultiScore) of Proteinâ 'Ligand Binding Affinities. Journal of Medicinal Chemistry, 2001, 44, 2333-2343.	2.9	110
58	Structural Differences of Matrix Metalloproteinases. Homology Modeling and Energy Minimization of Enzyme-Substrate Complexes. Journal of Biomolecular Structure and Dynamics, 2000, 17, 933-946.	2.0	22
59	Conformational Analysis and Pharmacophore Identification of Potential Drugs for Osteoporosis. , 2000, , 373-374.		O
60	Towards an understanding of drug resistance in malaria: Three-dimensional structure of Plasmodium falciparum dihydrofolate reductase by homology building. Bioorganic and Medicinal Chemistry, 1999, 7, 1003-1011.	1.4	52
61	Molecular Mechanics Calculations of Proteins. Comparison of Different Energy Minimization Strategies. Journal of Biomolecular Structure and Dynamics, 1997, 15, 473-488.	2.0	22
62	Conformational analysis of six- and twelve-membered ring compounds by molecular dynamics. , 1997, 11, 385-394.		14
63	Substrate binding and catalytic mechanism in phospholipase C fromBacillus Cereus: A molecular mechanics and molecular dynamics study., 1997, 42, 319-336.		18
64	Crystallization and preliminary X-ray analysis of a PNA-DNA complex. FEBS Letters, 1995, 363, 115-117.	1.3	8
65	GABAA Receptor Agonists, Partial Agonists, and Antagonists. Design and Therapeutic Prospects. Journal of Medicinal Chemistry, 1994, 37, 2489-2505.	2.9	99
66	Substrate-enzyme interactions and catalytic mechanism in phospholipase C: A molecular modeling study using the GRID program. Proteins: Structure, Function and Bioinformatics, 1992, 12, 331-338.	1.5	26
67	Primary structure and conformational analysis of peptide methionine-tyrosine, a peptide related to neuropeptide Y and peptide YY isolated from lamprey intestine. FEBS Journal, 1991, 199, 293-298.	0.2	47
68	Relationship between structure, conformational flexibility, and biological activity of agonists and antagonists at the N-methyl-D-aspartic acid subtype of excitatory amino acid receptors. Journal of Medicinal Chemistry, 1990, 33, 374-380.	2.9	20
69	Cyclic Acetals. Structural Analysis of 1,3-Dioxepine and Related Compounds. Helvetica Chimica Acta, 1985, 68, 2148-2157.	1.0	4
70	Cyclynes. Part 5. Pericyclynes: "exploded cycloalkanes" with unusual orbital interactions and conformational properties. MM2 and STO-3G calculations, x-ray crystal structures, photoelectron spectra, and electron transmission spectra. Journal of the American Chemical Society, 1985, 107, 6556-6562.	6.6	49
71	Crystal and molecular structure of anti-sesquinorbornene. Journal of Organic Chemistry, 1985, 50, 4395-4397.	1.7	12
72	cis-disulfides protelectron spectrum of a 6,7-dithiabicyclo[3.2.1]octane. Tetrahedron Letters, 1983, 24, 319-322.	0.7	8

#	Article	IF	CITATIONS
73	On the presence of extremely short $H\hat{a} \in H$ non-bonded distances, and orbital interactions through eight H bonds or through two methylene groups in tetramethanonaphthacenes Tetrahedron Letters, 1983, 24, 5415-5418.	0.7	6
74	Crystal structure of merosinigrin, an (ap,ap)-monothioacetal; structural properties of the thioglycosidic linkage. Carbohydrate Research, 1983, 123, 1-11.	1.1	14
7 5	betaThioxo ketones. 8. X-ray photoelectron-spectroscopic study of the enol-enethiol tautomerism of thioacetylacetone and related betathioxo ketones. Journal of the American Chemical Society, 1982, 104, 5922-5926.	6.6	20
76	Correlations between core photoionization energies (EB1s) and gas-phase basicity. A general method for determining sites of protonation and intramolecular ion reorganization energies. Journal of the American Chemical Society, 1982, 104, 5019-5025.	6.6	17
77	Anti,anti acetals. Tetrahedron Letters, 1982, 23, 5221-5224.	0.7	13
78	The electronic structure of .betathioxoketones. A photoelectron spectroscopic study of the enol-enethiol tautomerism of thioacetylacetone and related compounds. Journal of the American Chemical Society, 1981, 103, 1350-1353.	6.6	26
79	Polyethers. Tetrahedron, 1981, 37, 3671-3679.	1.0	10
80	Search for a trans-disulfide: structural analysis of di-tert-adamantyl disulfide by photoelectron spectroscopy, derivation of .sigma.l(t-Ad), and molecular mechanics calculations for related bulky disulfides. Journal of Organic Chemistry, 1980, 45, 1015-1020.	1.7	23
81	Crystal and molecular structure of di-tert-adamantyl disulfide. Extension of the correlation between the sulfur-sulfur dihedral angle and the sulfur lone-pair energy gap. Journal of Organic Chemistry, 1980, 45, 5343-5347.	1.7	18
82	Disulfide conformational analysis. Tetrahedron, 1979, 35, 1399-1407.	1.0	29